Australian firm ChemGenex Pharmaceuticals announced hopes of collaborating with other companies to market its cancer drug omacetaxine within the next six months. Intended for patients with drug-resistant leukemia, omacetaxine leads a class of experimental medicines that target the T315I gene mutation, which causes resistance to leukemia treatment Gleevec.

Full Story:

Related Summaries